Biomaterials for intranasal and inhaled vaccine delivery
Source abstract
Abstract
Delivery of vaccines by nasal sprays may enable more robust, protective mucosal immune responses against infectious diseases, such as COVID-19, compared with intramuscular injection. In this Comment, we highlight how biomaterials can be designed to allow intranasal and inhaled vaccination.
The source flagged this abstract for review. Check formulas and completeness against the original publication.
Source: europepmc · Quality: needs review · Source record ↗
Source flags: short_text
Source flags: short_text
Research context
OpenAlex topics: Inhalation and Respiratory Drug Delivery · SARS-CoV-2 and COVID-19 Research · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (10)
Show source-provided references
1. Topol, E. J. & Iwasaki, A. Operation nasal vaccine — lightning speed to counter COVID-19. Sci. Immunol. 74, Eadd9947 (2022).10.1126/sciimmunol.add9947 ↗
2. Mao, T. et al. Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. Science 378, eabo2523 (2022).10.1126/science.abo2523 ↗
3. Hida, K. et al. Common gene therapy viral vectors do not efficiently penetrate sputum from cystic fibrosis patients. PloS One 6, e19919 (2011).10.1371/journal.pone.0019919 ↗
4. Kim, Y. C. et al. Strategy to enhance dendritic cell-mediated DNA vaccination in the lung. Adv. Ther. 4, 2000228 (2021).10.1002/adtp.202000228 ↗
5. Alameh, M.-G. et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity 54, 2877–2892 (2021).10.1016/j.immuni.2021.11.001 ↗
6. Li, M. et al. Engineering intranasal MRNA vaccines to enhance lymph node trafficking and immune responses. Acta Biomater. 64, 237–48 (2017).10.1016/j.actbio.2017.10.019 ↗
7. Wang, Z. et al. Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine. Nat. Biomed. Eng. 6, 791–805 (2022).10.1038/s41551-022-00902-5 ↗
8. Si, Y., Wen, Y., Kelly, S. H., Chong, A. S. & Collier, J. H. Intranasal delivery of adjuvant-free peptide nanofibers elicits resident CD8+ T cell responses. J. Control. Release 282, 120–130 (2018).10.1016/j.jconrel.2018.04.031 ↗
9. Hartwell, B. L. et al. Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity. Sci. Transl Med. 14, eabn1413 (2022).10.1126/scitranslmed.abn1413 ↗
10. Zhuo, S.-H. et al. A chitosan-mediated inhalable nanovaccine against SARS-CoV-2. Nano. Res. 15, 4191–4200 (2022).10.1007/s12274-021-4012-9 ↗